<DOC>
	<DOCNO>NCT00354913</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , hydroxyurea , work different way stop growth tumor cell , either kill cell stop divide . Giving imatinib mesylate together hydroxyurea may kill tumor cell . PURPOSE : This phase II trial study well give imatinib mesylate together hydroxyurea work treat patient recurrent progressive meningioma .</brief_summary>
	<brief_title>Imatinib Mesylate Hydroxyurea Treating Patients With Recurrent Progressive Meningioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate activity imatinib mesylate hydroxyurea , measure 6-month progression-free survival , patient recurrent progressive meningioma . Secondary - Evaluate progression-free survival ( PFS ) - Overall survival ( OS ) , - Objective response rate among patient treat regimen . OUTLINE : This open-label study . Patients receive oral imatinib mesylate twice daily oral hydroxyurea twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 21 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm meningioma Recurrent progressive disease prior surgical resection Measurable disease contrastenhanced MRI Multifocal disease allow No evidence intratumor hemorrhage pretreatment diagnostic imaging Stable postoperative grade 1 hemorrhage allow No peripheral edema central systemic fluid collection ≥ grade 2 ( e.g. , pericardial effusion , pulmonary effusion , ascites ) PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count &gt; 1,500/mm³ Hemoglobin &gt; 9 g/dL Platelet count &gt; 100,000/mm³ Potassium normal* Calcium normal* Magnesium normal* Phosphorus normal* alanine aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No excessive risk bleeding , define stroke within past 6 month No active systemic bleeding ( i.e. , gastrointestinal bleeding gross hematuria ) No history central nervous system ( CNS ) intraocular bleed septic endocarditis No concurrent severe and/or uncontrolled medical disease , include follow : Uncontrolled diabetes Congestive cardiac failure Myocardial infarction within past 6 month Poorly control hypertension History labile hypertension History poor compliance antihypertensive regimen Chronic renal disease Active uncontrolled infection require intravenous antibiotic No acute chronic liver disease ( i.e. , hepatitis , cirrhosis ) No HIV positivity No impairment gastrointestinal function disease may significantly alter absorption imatinib mesylate , include follow : Ulcerative disease Uncontrolled nausea Vomiting Diarrhea Malabsorption syndrome Bowel obstruction Inability swallow tablets No malignancy within past 5 year except basal cell skin cancer cervical carcinoma situ NOTE : *Unless correctable supplement PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 1 week since prior tumor biopsy More 2 week since prior surgical resection Prior hydroxyurea allow provided patient progressive disease toxicity &gt; grade 3 No prior imatinib mesylate plateletderived growth factordirected therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) * Chemotherapeutic agent etoposide normally give short interval allow even &lt; 4 week last prior dose chemotherapy At least 4 week since prior radiotherapy* At least 1 week since prior biological , immunotherapeutic , cytostatic drug At least 2 week since prior investigational drug No concurrent warfarin NOTE : *Unless unequivocal evidence tumor progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult papillary meningioma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>glioblastoma multiforme ( GBM )</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Droxia</keyword>
	<keyword>Hydrea</keyword>
	<keyword>Hydroxycarbamide</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Meningioma</keyword>
</DOC>